FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Biologics

Omeros, FDA Agree on Narsoplimab Primary Endpoint

Omeros and FDA agree to a response-based primary endpoint for its pivotal trial to support a BLA for narsoplimab to treat hematopoietic stem cell tran...

Human Drugs

Neurocrine Biosciences Opicapone NDA Accepted

FDA accepts for review a Neurocrine Biosciences NDA for opicapone, a once-daily, oral, selective catechol-O-methyltransferase inhibitor as an adjuncti...

Human Drugs

Reckitt Benckiser Settles Suboxone Marketing Cases for $1.4 Billion

The Virginia U.S. Attorney outlines a $1.4 billion settlement with Reckitt Benckiser to resolve civil and criminal cases involving marketing of its Su...

Medical Devices

FDA Qualifies Device Assessment Model Tool

FDA scientists develop and qualify a Tissue Mimicking Material for Preclinical Acoustic Performance Characterization Of High Intensity Therapeutic Ult...

Human Drugs

FDA Recognizes All EU States Under MRA

FDA says it has assessed all 28 European Union member states under the FDA/EU Mutual Recognition Agreement (MRA), which allows the agency to recognize...

Medical Devices

Pennsylvania Courts Assess Medical Device Strict Liability

A Washington Legal Foundation posts reviews a Pennsylvania case determining whether strict liability claims may be allowed for prescription medical de...

Human Drugs

2 Guidances to Speed Generic Drug Development

FDA issues two draft guidances aimed at speeding generic drug development and marketing.

Federal Register

New Animal Drug Residue Tolerances Final Rule

Federal Register final rule: FDA issues a final rule to revise the animal drug regulations for new animal drug residue tolerances.

Federal Register

Guide on REMS Modifications and Revisions

Federal Register notice: FDA releases a guidance entitled Risk Evaluation and Mitigation Strategies: Modifications and Revisions that outlines how to ...

Medical Devices

Live Case Presentations in Device Trials Guide

FDA posts a final guidance entitled Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials.